

- B cell receptors
activation of, 372e-19–20, 372e-20f
for antigen, 372e-1
defective rearrangements of, 2108
- BCG (Bacille Calmette-Guérin) vaccine, 1120, 1128
- BCL1* gene mutations, 101e-3t
- BCL2* gene mutations, 101e-3t
- BCL2* proteins, 102e-9–10, 102e-9f, 103e-6, 444e-9
- BCL6* gene mutations, 703
- BCNU. *See* Carmustine (BCNU)
- BCR-ABL1* oncogene, 41, 687–688, 688f, 689–690. *See also* Chronic myeloid leukemia (CML)
- BCX4430, 1328
- bdNA (branched-chain DNA) tests, 150e-7–8, 1247, 1247t
- BDNF (brain-derived neurotrophic factor), 444e-7t
- Beau's line, 380
- Beck Depression Inventory, 93
- Becker's disease, 462e-18
- Becker's muscular dystrophy, 462e-8
clinical features of, 462e-5t, 462e-8
diagnosis of, 462e-8
early interventions for, 450t
genetic considerations in, 436, 462e-5t
genetic testing for, 450t
treatment of, 462e-8
- Beck's triad, 1573
- Beckwith-Wiedemann syndrome, 83e-7, 439
- Beclomethasone dipropionate, 1679
- Bedaquiline, 205e-7, 1115, 1118–1119
- Bedbugs, 2750
- Bed nets, insecticide-treated, 14, 796
- Beef tapeworm. *See* *Taenia saginata*
- Beer potomania, 300, 301, 302
- Bee sting, 2116, 2748–2749
- Beetle vesication/dermatitis, 2750
- Bevor's sign, 2651
- Behavioral therapy. *See* Cognitive behavioral therapy (CBT)
- Behçet's syndrome, 2194
clinical features of, 2194
aortic aneurysm, 1638
chronic meningitis, 909t
cutaneous, 356t, 2194
diarrhea, 270
dysuria, 60e-1
neurologic, 441e-11f, 2194
ocular, 200, 2194
oral, 237, 239t
vasculitis, 2192, 2194
definition of, 2194
diagnosis of, 2194, 2194t
epidemiology of, 2194
genetic considerations in, 2194
HLA gene association with, 373e-7, 373e-8t
inflammasome activity in, 372e-8t
KIRs with, 372e-15t
pathogenesis of, 2194
treatment of, 2194
- Bejel. *See* Endemic syphilis
- Belatacept, 1829, 1829t
- Belimumab
adverse effects of, 2130t
for SLE, 2128f, 2130t, 2132, 2133
- Belladonna alkaloids, 473e-8t
- Bellini (collecting) duct tumors, 578, 578t. *See also* Renal cell carcinoma (RCC)
- Bell's palsy, 2647
antiviral therapy for, 1178
clinical features of, 2647
diagnosis of, 2648
differential diagnosis of, 2648
etiology of, 1178
imaging in, 441e-24f, 2648f
incidence of, 2647
oral pain in, 237
pathophysiology of, 2648
in pregnancy, 49
in relapsing fever, 1147
taste disorders in, 215
treatment of, 2648
- Bell's phenomenon, 2647
- Bence Jones proteins
laboratory evaluation of, 293, 1859, 1859f
in multiple myeloma, 293, 712, 715
reference values for, 2758t
- Bendamustine, 103e-8, 703, 704, 718
- Benedikt's syndrome, 208
- Benevolence, 17e-2
- Benign familial hematuria, 1847
- Benign familial neonatal seizures, 2545t
- Benign forgetfulness of the elderly, 171
- Benign hereditary chorea of childhood, 2622
- Benign paroxysmal positional vertigo, 149t, 150, 150f
- Benign prostatic hypertrophy (BPH)
clinical features of, 7e-4, 60e-1, 587, 1872
diagnosis of, 7e-4, 587, 587t
PSA levels in, 581
treatment of, 587
- Benign recurrent intrahepatic cholestasis (BRIC), 284, 2003t, 2004, 2076
- Benserazide/levodopa, 2614, 2616t
- Benzathine penicillin
for endemic treponematoses, 207e-3
for pharyngitis, 233, 965t
for rheumatic fever, 2152
for syphilis, 880t
- Benzbromarone, 2234
- Benzene exposure, 477t, 663, 678
- Benznidazole
action of, 246e-8
adverse effects of, 246e-3t, 246e-8, 1396, 1560
for Chagas disease, 246e-8, 1266, 1396, 1560
pharmacology of, 246e-8
- Benzoate, 434e-5
- Benzodiazepine(s). *See also specific drugs*
for acute alcohol intoxication, 2727
adverse effects of, 168, 478e-1
for alcohol withdrawal, 2727
for anxiety disorders, 2709–2710, 2711t
for delirium, 170
for dyspnea, 62
for insomnia, 62, 191
in mechanical ventilation, 1741
for nausea and vomiting, 260t, 261
in opiate overdose management, 468e-3
overdosage/poisoning with, 473e-10t
pharmacology of, 2711t
for restless legs syndrome, 192
for stress disorders, 2712
withdrawal from, 169, 2710–2551
- Benzonatate, 245
- Benzoyl peroxide, 352
- Benzphetamine, 2396
- Benztropine, 65, 2615, 2722
- Benzylpenicillin, 991
- BEP regimen, 590, 594
- Bereavement, 64, 69, 275
- Berg Balance Scale, 78t
- Beriberi. *See also* Thiamine (vitamin B₁) deficiency
cardiac manifestations of, 252, 290e-1–2, 1563
clinical features of, 96e-1t, 96e-2–3
dry, 96e-3, 2690
wet, 96e-2–3, 463t, 2690
- Berkelium exposure, 263e-7
- Berlin Questionnaire, 1721
- Bermejo virus, 1307t
- Bernard-Soulier syndrome, 729, 730
- Bernoulli effect, 306e-2
- Berry aneurysm, 1784–1785. *See also* Subarachnoid hemorrhage
- Beryllium, 1688t, 1691
- Beryllium disease/toxicity, 367, 373e-7, 1691
- Beryllium lymphocyte proliferation test, 1691
- β -adrenergic agonists
actions of, 265e-4, 265e-6, 265e-7f, 1676
adverse effects of, 65, 267, 305, 312, 1676
for asthma, 1676, 1679, 1679t
for COPD, 1705, 1707
for cough, 245
for high-altitude pulmonary edema, 476e-4
for hyperkalemia, 312
overdosage/poisoning with, 473e-3, 473e-8t
safety of, 1676
tolerance to, 1676
- β -adrenergic antagonists (beta blockers)
for accessory pathway-mediated tachycardia, 1483
for acute angle-closure glaucoma, 200
adverse effects of, 36, 1588–1589
alopecia, 354
arthralgias, 2218t
in asthma, 1671
AV conduction block, 1471t
cutaneous, 347, 353, 378
erectile dysfunction, 326
hair loss, 380
heat-related illness, 479e-1
Raynaud's phenomenon, 1649
SA node dysfunction, 1467t, 1469
xerostomia, 241
aldosterone-renin ratio effects of, 2320t
for aortic aneurysm, 1639, 1640
for aortic dissection, 1641
for atrial fibrillation, 1487–1488
for AV nodal reentrant tachycardia, 1479
contraindications to, 1588, 1603–1604, 2117
for cyclic vomiting syndrome, 261
drug interactions of, 43, 246e-10, 2711t
genetic variations in response to, 40
for glaucoma, 205
for heart failure, 1511, 1511f, 1512t
for hypertension, 1623–1624, 1624t
for hypertrophic cardiomyopathy, 1570
for inappropriate sinus tachycardia, 1477
for ischemic heart disease, 1588–1590, 1589t
for migraine prevention, 2593
for myocardial infarction, 1596, 1597t, 1603–1604, 1607, 1610
overdosage/poisoning with, 473e-9t, 473e-13t
for palpitations, 254
perioperative, 53–54
in peripheral artery disease, 1644, 1645
for pheochromocytoma, 2331
for phobic disorders, 2712
for radiation-induced cardiovascular disease, 621
for respiratory alkalosis, 324
for syncope, 145
for variceal bleeding, 277, 2063
for ventricular tachycardia, 1498
- β -adrenergic receptors, 37f, 40, 1613, 1745
- Beta blockers. *See* β -adrenergic antagonists (beta blockers)
- β -carotene
cancer and, 96e-7
for erythropoietic protoporphyria, 390, 2533
excess of, 463t
for lung cancer prevention, 477
for macular degeneration, 205
- Beta diversity, 86e-1t, 86e-5
- β -globin gene mutations, 433f, 435
- β -glucan test, 1330
- β_2 -glycoprotein, 372e-24t. *See also* Anti- β_2 -glycoprotein antibodies
- β -hemolytic streptococcal infections. *See* Group A *Streptococcus* (GAS) infections; Group B *Streptococcus* (GBS) infections
- β -IV spectrin, 372e-25t
- β -lactam antibiotics
action of, 930, 931t, 932f, 936–937
adverse effects of, 138, 938t, 942
for anaerobic bacterial infections, 1101
for cystic fibrosis, 1699
for cystitis, 867, 867t
for infective endocarditis, 963
for *P. aeruginosa* infections, 1044
for pneumococcal infections, 952
for pneumonia, 767t
resistance to
in anaerobic bacteria, 1101
detection of, 807
in *Klebsiella*, 1033
mechanisms of, 931t, 933, 976
 β -lactamase, 933, 1026, 1037